Reyataz (Atazanavir)

The Latest

An Overview of Reyataz (Atazanavir)

Brand Name: Reyataz Other Name(s): ATV, atazanavir sulfate Drug Class: Protease Inhibitors

By AIDSinfo

Atazanavir (Reyataz)

Table of Contents

What Is Atazanavir? Who Should Take It? What About Drug Resistance? How Is It Taken? What Are the Side Effects? How Does It React With Other Drugs?

What Is Atazanavir?

Atazanavir, also called Reyataz, is a drug used as ...

By AIDS InfoNet

Reyataz

Brand name: Reyataz

Generic name: atazanavir sulfate (atazanavir), or ATV

Class: Protease inhibitor (PI)

Manufacturer: Bristol-Myers Squibb, www.reyataz.com, (800) 321-1335

AWP: $1,219.09/month for 300 mg capsules; $1,257.09/month for 200 mg caps...

By Positively Aware

Reyataz (Atazanavir)

Reyataz capsules are dark blue (200 mg) or half dark blue and half light blue (150 mg). The capsules are labeled with "BMS," the dose, and a 4-digit number ("3631" for the 200 mg or "3624" for the 150 mg). Dosing may vary. [Not shown: 100-mg capsule,...

By The Center for AIDS Information & Advocacy

Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra

On March 19, 2004 the FDA notified the public of new prescribing information and precautions for atazanavir (brand name Reyataz), if taken in combination with tenofovir (Viread) -- and warned of risks with Viagra or similar drugs.

If atazanavir is t...

By AIDS Treatment News

Two Pills Once a Day. No Cholesterol or Triglyceride Issues? You Say This Is a Protease Inhibitor? Atazanavir (Reyataz) Gains FDA Approval

Armed with a hell of a lot more data than President Bush had when he took us to war with Iraq, Bristol Myers Squibb gained FDA approval for their new protease inhibitor (PI) atazanavir (Reyataz®). It's the first new protease inhibitor to hit the mark...

By Shelley Cohen McKittrick for PWA Coalition Colorado

Population Pharmacodynamic (PD) Assessment of the Safety and Antiretroviral Activity of BMS-232632

Population Pharmacodynamic (PD) Assessment of the Safety and Antiretroviral Activity of BMS-232632 Abstract 507 Authored by E. Omara (Bristol-Myers Squibb, Princeton, NJ), B. Cirincione (Cognigen Corp., Buffalo, NY), V. Mummaneni (Bristol-M...

By Brian A. Boyle, M.D., J.D.

BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers

This study is one of several posters on new protease inhibitors that are under development. In particular, BMS-232632 shows an EC50 value ranging from 25 nM. This is a report of a single dose study and some preliminary results from ongoing multiple d...

By Donald L. Kaminsky, M.D.

Anti-Viral Activity and Resistance Profile of an HIV-1 Protease Inhibitor BMS-232632

This presentation by Gong and colleagues at Bristol-Myers Squibb provides in vitro and limited in vivo data of a new protease inhibitor in development that promises desirable features of once daily dosing, good tolerability and a resistance profile t...

By Jim Thommes, M.D.